Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

    Vous êtes ici :  
  1. Accueil
  2. Blog With Right Sidebar

History of allergic diseases and lung cancer risk.

The exact nature and direction of the association between a history of allergic diseases and lung cancer risk remain controversial.

OBJECTIVE: To examine the association between self-reported history of allergic diseases and lung cancer using data from a population-based case-control study conducted in the Montreal metropolitan area (1996-2002).

METHODS: The study is based on interview data collected from 1,169 incident lung cancer cases and 1,486 controls. Separate logistic regression models were used to estimate the relative risk of lung cancer, using odds ratios (ORs) and 95% confidence intervals (CIs), in subjects with vs without asthma, eczema, or hay fever after adjustment for several sociodemographic and lifestyle factors, including smoking.

RESULTS: For asthma, the OR was 0.90 (95% CI 0.65-1.24), which decreased to 0.76 (95% CI 0.54-1.08) for subjects whose onset was more than 2 years before lung cancer diagnosis or interview and then to 0.64 (95% CI 0.44-0.93) when restricted to subjects who reported using medication for their asthma. For eczema, the point estimate was 0.73 (95% CI 0.48-1.12), which decreased to 0.63 (95% CI 0.38-1.07) when considering eczema only in those who reported medication use. Hay fever showed the strongest inverse association with lung cancer (OR 0.37, 95% CI 0.24-0.59).

CONCLUSION: All 3 allergic diseases examined were inversely associated with lung cancer, although the strength of the protective effect varied. History of allergic diseases seems to have a protective role in lung cancer incidence, after consideration of potential confounders, including lifetime smoking history.

Update of the WHO/IUIS Allergen Nomenclature Database based on analysis of allergen sequences

Abstract The IUIS Allergen Nomenclature Sub‐Committee, under the auspices of the World Health Organization and the International Union of Immunological Societies, maintains the systematic nomenclature of allergenic proteins and publishes a database of approved allergen names on its Web site, www.allergen.org. In this paper, we summarize updates of allergen names approved at the meetings of the committee in 2011 through 2013. These changes reflect recent progress in identification, cloning, and sequencing of allergens. The goals of this update were to increase consistency in the classification of allergens, isoallergens, and variants and in the incorporation of the evolutionary classification of proteins into allergen nomenclature, while keeping changes of established names to a minimum i...

Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position

Conclusion Whenever the question arises `Might an operation help me?' there are two responses that can and should be given. The first is that there is doubt about whether there is any survival or symptomatic benefit from surgery but we know that there is harm. The second is that there are on-going studies, including two randomised trials, which patients should be informed about. The authors suggest that the default position for clinicians should be to encourage recruitment into these trials. (Source: Thorax)

Pesticides and respiratory health: where do we go from here?

For centuries, researchers have focused on exposures to hays, grains and animals as primary contributors to poor respiratory outcomes in farmers and agricultural workers.1 2 However, growing evidence suggests that other agricultural exposures, namely pesticides, may also adversely impact respiratory health. Recent studies from around the world have suggested that pesticides may be associated with respiratory symptoms and disease, particularly asthma.3–6 However, these studies have been based on self-reported outcomes and there have been few studies using objective measures of pulmonary function.2 7 De Jong et al8 report that occupational pesticide exposure is associated with poorer pulmonary function consistent with airway obstruction as measured by spirometry in two Dutch general po...

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Conclusion: In patients with moderate-to-severe COPD, 12-week blinded treatment with once-daily glycopyrronium 50 mug or tiotropium 18 mug, provided similar efficacy and safety, with glycopyrronium having a faster onset of action on Day 1 versus tiotropium.Trial registration: ClinicalTrial.gov: NCT01613326 (Source: BMC Pulmonary Medicine - Latest articles)

Search

Search